Sarepta Therapeutics【0L35】銘柄情報

Sarepta Therapeutics Inc (0L35) 銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

90.83

( - )

買値

90.83

売値

90.83

出来高

31,540

0.00 日の範囲 0.00

90.83 52 週間の範囲 90.83

時価総額

9.589B

前日終値

90.83

始値

時刻

124

17.24

(O)

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

US$ 3,066,233

発行済株式数

105,576,222

配当利回り

PER

24.01

1 株当たり利益 (EPS)

0.8

歳入

2.18B

純利益

65.06M

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchen... Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children’s Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. 詳細を表示

セクター

業界

ウェブサイト

www.sarepta.com

本社

Cambridge, United States

設立

1980

Sarepta Therapeutics Inc is listed in the sector of the ロンドン証券取引所 with ticker 0L35. The last closing price for Sarepta Therapeutics was US$90.83. Over the last year, Sarepta Therapeutics shares have traded in a share price range of US$ 90.83 to US$ 90.83.

Sarepta Therapeutics currently has 105,576,222 shares in issue. The market capitalisation of Sarepta Therapeutics is US$9.59 billion. Sarepta Therapeutics has a price to earnings ratio (PE ratio) of 24.01.

表示するニュースはありません。

期間 †	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	DE
4	0	0	0	0	0	DE
12	0	0	0	0	0	DE
26	90.83	90.83	90.83	7660	90.83	DE
52	90.83	90.83	90.83	25315	90.83	DE
156	90.83	90.83	90.83	8164	90.83	DE
260	90.83	90.83	90.83	5396	90.83	DE